Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout
Myasthenia gravis POC readout closely preceded pharma’s premium bid
A proof-of-concept readout in generalized myasthenia gravis closely preceded the pharma’s premium bid.
Momenta’s 2018 decision to reorganize its business around its innovative pipeline was the critical step that positioned the biotech for its $6.5 billion takeout by J&J, announced Wednesday.
The company had deprioritized its complex generics and biosimilars businesses nearly two years